Cardio-renal-metabolic disease in primary care setting

Area of Science:

• Endocrinology
• Primary Care Medicine
• Cardiovascular Disease Management

Background:

• Primary care settings offer expanded therapeutic options for obesity, diabetes, and associated renal and cardiac conditions.
• Recognizing diabetes heterogeneity is crucial for effective treatment strategies.
• Newer hyperglycemic treatments offer mortality and macrovascular benefits beyond glucose control.

Purpose of the Study:

• To review the latest tools and treatments for managing type 2 diabetes (T2DM) in primary care.
• To provide recommendations for the optimal use of novel medications, including SGLT2 inhibitors and GLP-1 receptor agonists.
• To highlight the role of technology in improving diabetes care and predicting complications.

Main Methods:

• Review of current literature on T2DM management in primary care.
• Analysis of the benefits and applications of new pharmacotherapies (SGLT2i, GLP1RA).
• Evaluation of technological advancements such as continuous glucose monitoring (CGM) and predictive algorithms.

Main Results:

• Newer medications (SGLT2i, GLP1RA) demonstrate significant benefits in reducing mortality, macrovascular complications, and heart failure.
• Continuous glucose monitoring (CGM) improves glycemic control (HbA1c) and reduces hypoglycemia.
• Predictive algorithms show potential for risk stratification but require further refinement.

Conclusions:

• Primary care providers are equipped with effective strategies to manage T2DM and its complications.
• Optimal utilization of SGLT2 inhibitors and GLP-1 receptor agonists is recommended, even in early T2DM stages.
• Technological integration, including CGM and predictive analytics, enhances diabetes care quality and patient outcomes.